The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2024 class will be inducted at an event during SITC’s 39th Annual Meeting & Pre-Conference Programs, taking place November 6–10, 2024 in Houston, TX.
MILWAUKEE, Aug. 5, 2024 /PRNewswire-PRWeb/ — The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2024 class will be inducted at an event during SITC’s 39th Annual Meeting & Pre-Conference Programs, taking place November 6–10, 2024 in Houston, TX.
“Each year, we honor those who have made seminal contributions to move the field of cancer immunotherapy forward to the benefit of patients,” said SITC President Leisha A. Emens, MD, PhD.
“Each year, we honor those who have made seminal contributions to move the field of cancer immunotherapy forward to the benefit of patients,” said SITC President Leisha A. Emens, MD, PhD. “SITC is proud to welcome this slate of incredible individuals to the 2024 class and is excited to honor them at the 39th Annual Meeting in Houston this November.”
2024 Class of the Academy:
Glenn Dranoff, MD – Dana-Farber Cancer Institute
Tom Gajewski, MD, PhD – University of Chicago
Ira Mellman, PhD – Genentech
Antoni Ribas, MD, PhD – University of California Los Angeles
Jedd Wolchok, MD, PhD, FAACR, FASCO – Weill Cornell Medicine
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy
SITC solicits nominations and inducts a new class of FAIO on an annual basis. The next call for nominations will be in the spring of 2025.
The Academy of Immuno-Oncology was established by SITC to honor individuals who have launched the field of cancer immunotherapy into the breakthrough cancer treatment it is today, bringing together the brightest minds in the field in order to inspire the next generation of immuno-oncologists.
About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, Facebook, Instagram and YouTube.
Media Contact
Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, tmartin@sitcancer.org, sitcancer.org
Twitter
View original content to download multimedia:https://www.prweb.com/releases/sitc-announces-2024-class-of-fellows-to-the-academy-of-immuno-oncology-302214429.html
SOURCE Society for Immunotherapy of Cancer
